Tag:
TetraLogic
Latest Headlines
Latest Headlines
Ex-Amgen drug researcher calls out questionable cancer findings
Drug developers have fresh reasons to doubt their ability to translate cancer research wins into anti-tumor treatments.
TetraLogic pushes Series C to $37M
Malvern, PA-based TetraLogic has added $5 million to a previously announced $32 million Series C, bringing the developer's total haul for this round to $37 million. Pfizer Ventures added the extra
TetraLogic nabs $32M round for lead cancer therapy
Malvern, PA-based TetraLogic Pharmaceuticals has rounded up $32 million in Series C cash to back the development of its lead cancer drug, the early-stage TL32711. Clarus Ventures led the round with
